What Is Goserelin Approved For? Label Indications, Per the Research

Goserelin is a prescription medicine in the gonadotropin releasing hormone (GnRH) agonist class. It is a synthetic analogue of the natural decapeptide GnRH, built with modified residues that resist rapid enzymatic breakdown; a 2022 medicinal chemistry review placed goserelin among the clinically used azapeptides, molecules in which a backbone carbon is replaced by nitrogen to change stability and receptor behaviour (PMID 35538801). Continuous stimulation of the pituitary GnRH receptor by such agonists ultimately suppresses the release of luteinising hormone, which lowers circulating sex hormones. That pharmacology explains why the approved indications cluster in hormone driven conditions.

This page is for educational purposes only and is not medical advice; consult a licensed physician or the prescribing clinician for any question about whether a medicine is appropriate, and do not treat anything here as instruction.

The Approved Indications at Label Level

Approved labeling for goserelin containing products describes a small, defined set of uses. The table below summarises those categories in plain language. Exact indication wording, the depot strength to which each indication applies, the approval dates, and any restrictions by sex, menopausal status or disease stage are set out in the approved prescribing information and in the regulatory review documents published for each country, and those documents are the authoritative source rather than any summary.

Labels are not interchangeable across regions. Some national labels list additional or narrower wording, and the depot strengths available differ. A clinician with access to the current local prescribing information is the only reliable source for whether a particular indication applies to a particular product.

Prostate Cancer: What the Trial Literature Reports

Androgen deprivation is the shared mechanism behind the prostate indications. The most directly relevant randomised evidence in the verified set is the GETUG-AFU 16 trial, which tested short term androgen deprivation added to salvage radiotherapy after radical prostatectomy; researchers administered goserelin 10.8 mg subcutaneously alongside radiotherapy in the combination group (PMID 31629656). At a median follow up of 112 months, the study reported that progression free survival remained significantly better in the group that received radiotherapy plus short term androgen deprivation than in the group that received radiotherapy alone (PMID 31629656).

Two points matter for reading that trial against the label. First, the salvage setting after radical prostatectomy is a specific clinical scenario, and whether it falls inside a given country's approved wording is a question for the prescriber and the local prescribing information. Second, the reported outcome was progression free survival over long follow up, not a general claim about any other disease stage (PMID 31629656).

Breast Cancer: Ovarian Suppression in the Published Trials

In pre and perimenopausal women, the ovaries are the dominant source of oestrogen, so suppressing ovarian function is the pharmacological point of the breast cancer indication. Modern trial literature shows how that suppression is used as the backbone of combination endocrine regimens.

Advanced disease

MONALEESA-7 randomised premenopausal and perimenopausal women with hormone receptor positive advanced breast cancer to ribociclib or placebo on top of goserelin plus either tamoxifen or a non steroidal aromatase inhibitor, and the study reported significantly longer progression free survival with ribociclib (PMID 29804902). A later analysis of the same trial reported a significantly higher overall survival rate with ribociclib plus endocrine therapy than with endocrine therapy alone in this premenopausal population (PMID 31166679). In the palbociclib trial of fulvestrant based therapy for hormone receptor positive advanced breast cancer, pre and perimenopausal participants received ovarian suppression with goserelin as part of the protocol, and researchers reported longer progression free survival with palbociclib added to fulvestrant (PMID 26030518).

Early disease

The NATALEE trial studied patients with stage II or III hormone receptor positive, HER2 negative early breast cancer and reported significantly longer invasive disease free survival when ribociclib was added to a non steroidal aromatase inhibitor (PMID 38507751). A four year analysis of the same trial reported that the invasive disease free survival benefit persisted after the planned ribociclib treatment period ended (PMID 40996773). Early breast cancer management in premenopausal patients is an area of active trial work, and the published reports describe endocrine therapy backbones rather than any standalone claim about one component (PMID 40996773).

The approved breast cancer wording on goserelin labeling is narrower than the breadth of these trials. The label describes palliative treatment of advanced breast cancer in pre and perimenopausal women; it does not convert every regimen studied in a trial into an approved use. Whether a given regimen is appropriate is a conversation to have with a prescribing clinician.

Gynaecology: Endometriosis and Endometrial Thinning

The non oncology approvals follow the same hormonal logic. Suppressing ovarian oestrogen output reduces stimulation of endometrial and endometriotic tissue, which is the basis for the endometriosis indication and for the endometrial thinning indication before ablation for dysfunctional uterine bleeding. Both indications carry duration limits and monitoring expectations in the approved labeling, and those details belong to the prescribing information rather than to any summary page.

Research into alternative hormonal targets in endometriosis continues alongside the approved options. A pharmacological review assessed aldo-keto reductase 1C3 as a candidate target for endometriosis treatment, an approach that remains investigational and is not an approved indication for any GnRH agonist (PMID 31546014).

Investigational Uses Discussed in the Literature

Several uses appear in published studies without being approved indications. These are described here as investigational, which means studied but not carried on the label.

• Investigational: preoperative medical debulking before vaginal hysterectomy. A randomised controlled study examined whether treatment with a gonadotrophin releasing hormone agonist before surgery facilitated vaginal hysterectomy in women with a moderately enlarged uterus (PMID 23537617). Whether this use is covered by labeling depends entirely on the local prescribing information and the prescriber's judgement.
• Investigational: computational repurposing screens. A 2022 study used machine learning based virtual screening of existing drugs to identify candidates against Candida albicans infection, an early stage computational exercise rather than clinical evidence of any new indication (PMID 35639510).
• Investigational: newer combination partners in advanced breast cancer. A randomised clinical trial reported outcomes for fovinaciclib as first line therapy in advanced breast cancer, which illustrates how the endocrine therapy landscape keeps changing without altering what is currently on any individual product label (PMID 42224659).

None of the above should be read as an approved use. Approved means the indication appears in the regulatory authorised labeling for the product in question.

Adverse Events: What Studies Report

Adverse event information for the long acting GnRH agonist class has been studied in post marketing surveillance databases as well as in individual trials. A 2025 real world pharmacovigilance analysis compared reported adverse event profiles across long acting gonadotropin releasing hormone analogues and reported that the signal patterns were not identical between agents in the class (PMID 40644420). The authors framed the differences as hypothesis generating, since spontaneous reporting databases capture reports rather than verified incidence rates (PMID 40644420).

In the oncology trials above, tolerability reporting covered the whole regimen rather than one component in isolation. MONALEESA-7 reported safety outcomes for ribociclib added to goserelin plus endocrine therapy in premenopausal women (PMID 29804902), and the NATALEE four year analysis similarly reported tolerability alongside efficacy for the combination studied (PMID 40996773). Individualised risk questions, including bone health and cardiovascular considerations, belong with a prescribing clinician who can review the full prescribing information.

How to Read an Approval Question Correctly

1. Identify the exact product and strength. Depot strengths can carry different indication sets.
2. Identify the country. Indication wording and approval dates are country specific and are published in the regulatory documents for each market.
3. Separate trial evidence from label text. A positive trial, such as the 112 month GETUG-AFU 16 follow up (PMID 31629656), informs practice but does not by itself change an approved indication.
4. Ask the prescriber. Any question about whether an indication applies to a specific person is a clinical question, not a documentation question.

No dosing, preparation or administration guidance appears on this page by design. Study level doses are reported only where the cited paper reported them, as in the goserelin 10.8 mg subcutaneous regimen used in GETUG-AFU 16 (PMID 31629656), and such figures describe what researchers did in a trial rather than anything to replicate.

Key Takeaways

• Goserelin is a prescription GnRH agonist with a defined set of approved indications in prostate cancer, breast cancer in pre and perimenopausal women, endometriosis and endometrial thinning before ablation.
• Randomised trial evidence supports androgen deprivation combined with salvage radiotherapy in prostate cancer at long follow up (PMID 31629656) and ovarian suppression as the backbone of premenopausal breast cancer regimens (PMID 29804902).
• Preoperative fibroid debulking and computational repurposing hits remain investigational (PMID 23537617, PMID 35639510).
• Class level adverse event reporting differs between long acting GnRH analogues in pharmacovigilance data (PMID 40644420).
• Talk to your prescriber about any use question; this page summarises published literature and nothing more.

References

• Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial (The Lancet Oncology, 2019)
• Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial (The Lancet Oncology, 2018)
• Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (The New England Journal of Medicine, 2019)
• Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer (The New England Journal of Medicine, 2015)
• Ribociclib plus Endocrine Therapy in Early Breast Cancer (The New England Journal of Medicine, 2024)
• Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial (JAMA Oncology, 2025)
• Adverse event profile differences among long-acting gonadotropin-releasing hormone analogs: A real-world, pharmacovigilance study (PLoS One, 2025)
• Does medical debulking with gonadotrophin-releasing hormone agonist facilitate vaginal hysterectomy with a moderate enlarged uterus? A randomized control study (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2013)
• Aldo-keto reductase 1C3-Assessment as a new target for the treatment of endometriosis (Pharmacological Research, 2020)
• Azapeptides - A History of Synthetic Milestones and Key Examples (Current Medicinal Chemistry, 2022)
• Machine-learning-based virtual screening to repurpose drugs for treatment of Candida albicans infection (Mycoses, 2022)
• Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial (JAMA Oncology, 2026)